Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial to determine efficacy, safety and tolerability of imatinib delivered by IkT-001Pro in patients with WHO Class I PAH

Next Previous
Trial Profile

A clinical trial to determine efficacy, safety and tolerability of imatinib delivered by IkT-001Pro in patients with WHO Class I PAH

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 15 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IKT 001PRO (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 09 May 2024 According to an Inhibhikase Therapeutics media release, today announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001Pro as a candidate treatment for Pulmonary Arterial Hypertension (PAH). Following review of the final meeting minutes, company is preparing the Investigational New Drug (IND) application.
  • 08 Apr 2024 New trial record
  • 03 Apr 2024 According to an Inhibhikase Therapeutics media release, company plans a Pre-IND meeting with the FDA to discuss cardiopulmonary applications including Pulmonary arterial hypertension of IkT 001Pro in April 2024. The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top